GLP-2 Side Effects: What Studies Report

What "GLP-2 side effects" refers to in the published literature

Glucagon-like peptide-2 (GLP-2) is an endogenous intestinal hormone released by enteroendocrine L-cells. Because of its trophic action on intestinal mucosa, almost all of the human clinical literature involves people with short bowel syndrome (SBS) or intestinal failure, and almost all of it studies analogs of GLP-2 rather than the native peptide. Teduglutide is the GLP-2 analog approved by regulators for short bowel syndrome; apraglutide and glepaglutide have been described in the published literature as longer-acting GLP-2 analogs under clinical investigation, with glepaglutide characterised as a long-acting GLP-2 analog in a 2023 pharmacokinetics, safety and tolerability study (PMID 36811175).

That context matters for anyone reading about adverse events. Safety signals in this literature were collected in patients who were, by definition, medically complex: many were dependent on parenteral nutrition, had altered bowel anatomy, and were receiving multiple concurrent therapies. Published reports therefore describe adverse events occurring during treatment, not necessarily adverse events caused by treatment. This page maps which studies examined safety and what domains they monitored; per-symptom frequency tables live in the full primary reports, not in the summaries available here. Receptor biology and mechanism are covered separately in the PeptideU GLP-2 course, so this page stays with safety and tolerability intent.

Where the human safety data come from

The verified papers summarised below span adult SBS trials, a renal-impairment pharmacokinetic study, dedicated pediatric and infant safety studies, review articles on enterohormone therapy and intestinal adaptation, and one preclinical mouse study outside the gut.

Gastrointestinal and Abdominal Findings: What Studies Report

Gastrointestinal symptoms sit at the centre of this literature for a structural reason: GLP-2 analogs act on the gut, and the patients studied already had disordered gut function. In the 2024 apraglutide work, safety was named alongside efficacy as a study objective in adults with SBS with intestinal failure and colon-in-continuity, and the design was an open-label metabolic balance study (PMID 39461299). A metabolic balance design means intake and output were measured under controlled conditions, which is also how changes in stool volume, fluid handling and nutrient absorption become visible as either benefit or burden.

The 2025 glepaglutide report framed its endpoints as intestinal absorption and parenteral support in patients with short bowel syndrome (PMID 40774623). In practice, absorption-focused endpoints and tolerability overlap heavily, because the same physiological changes that reduce ostomy or stool output can also present as abdominal discomfort, distension or changes in stoma appearance. Reviews of enterohormone therapy for short bowel syndrome have discussed these therapies in the context of patient selection and ongoing monitoring rather than as uniformly tolerated interventions (PMID 35034035). Readers who want incidence percentages for individual symptoms should go to the full text of the trials themselves; this page does not reconstruct numbers that are not in the verified record.

Fluid Balance and Parenteral Support Changes: What Studies Report

One recurring theme is that GLP-2 analog therapy changes fluid and nutrient handling enough that parenteral support itself must be re-evaluated. The 2025 glepaglutide analysis reported outcomes on both intestinal absorption and parenteral support in short bowel syndrome (PMID 40774623), and a 2019 review in Gastroenterology Clinics of North America addressed weaning from parenteral nutrition as its own clinical problem (PMID 31668181).

This is a safety-adjacent domain rather than a classic adverse-event list. If absorption improves while intravenous fluid and electrolyte support continues unchanged, fluid overload becomes a plausible concern; if support is reduced too quickly, dehydration and electrolyte disturbance become the opposite concern. That is why reviews of enterohormone therapy treat monitoring and dose-support adjustment as part of the therapy rather than an afterthought (PMID 35034035). Nothing on this page should be read as instruction about managing parenteral support, which is a physician-supervised clinical activity.

Mucosal Growth and Longer-Term Monitoring: What Studies Report

GLP-2's defining pharmacology is intestinotrophic: it drives growth of intestinal mucosa. Chinese-language review work on intestinal adaptation after enterectomy has covered the mechanisms by which remnant bowel adapts, including hormonal drivers of that adaptation (PMID 36562240). A growth-promoting mechanism is exactly why long-term surveillance features in discussions of this drug class, and why duration of exposure matters in the published record. The 2025 pediatric report was explicitly framed as a three-year experience with a GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome (PMID 40875041), which makes it one of the longer observational windows in the verified set.

Multi-year, real-world follow-up is scarce across the whole GLP-2 field. Most controlled studies here were short, open-label or balance-study designs in small populations, so questions about cumulative exposure remain a matter for the primary literature and for treating clinicians rather than for general summary.

Kidney Function and Drug Exposure: What Studies Report

Organ function changes how much of a peptide analog circulates, and one verified paper addressed this directly. A 2023 study in Clinical Pharmacokinetics examined the pharmacokinetics, safety and tolerability of glepaglutide, a long-acting GLP-2 analog, in subjects with renal impairment (PMID 36811175). Studies of this kind exist because impaired clearance can raise exposure and, with it, the likelihood of dose-related effects. The existence of a dedicated renal-impairment study is itself informative: it signals that regulators and researchers treated exposure in comorbid populations as a safety question worth isolating.

Children and Infants: What Studies Report

Pediatric intestinal failure has its own GLP-2 literature, and notably it is built around safety-first designs. A 2017 study in JPEN was titled and structured as a safety and dosing study of glucagon-like peptide 2 in children with intestinal failure (PMID 26471991), and a separate 2017 report in the Journal of Pediatric Surgery examined safety and pharmacokinetic dosing of glucagon-like peptide 2 in infants with intestinal failure (PMID 28209419). Longer-term pediatric follow-up appeared in the 2025 three-year intestinal rehabilitation report in pediatric-onset short bowel syndrome (PMID 40875041).

These were small, specialised studies in infants and children who could not be maintained enterally without support. Their findings do not transfer to healthy children or adults, and none of the verified papers examined GLP-2 in people without intestinal disease.

Animal and Preclinical Findings: What Studies Report

Preclinical work has looked at GLP-2 outside the gut. A 2025 Nature Metabolism study reported that GLP-2 prevented antipsychotic-induced metabolic dysfunction in mice (PMID 40114026). That is a mechanistic finding in a rodent model, not a human safety result, and it does not establish metabolic effects — beneficial or adverse — in people. Adjacent literature on intestinal barrier function has also been reviewed from a nutrition perspective, with a 2021 Advances in Nutrition paper discussing prospects for nutraceutical support of intestinal barrier function (PMID 33126251), which is useful for understanding why barrier and mucosal endpoints recur in this field.

Why attributing side effects to GLP-2 is difficult

• Sick populations. Adults and children in these studies had intestinal failure, altered anatomy and ongoing parenteral support, as reflected in the populations described across the SBS reports (PMID 39461299, PMID 40774623).
• Open-label designs. The 2024 apraglutide study was described as multicenter and open-label (PMID 39461299), a design in which symptom reporting is not blinded.
• Overlapping endpoints. Absorption and parenteral support outcomes and tolerability outcomes describe the same physiology from different angles (PMID 40774623, PMID 31668181).
• Small numbers. Pediatric and infant safety studies were explicitly dosing and safety investigations in small cohorts (PMID 26471991, PMID 28209419).

What the literature does not establish

Within the verified record, several gaps are clear. No study here examined GLP-2 or its analogs in healthy adults, in athletic or cosmetic contexts, or for general "gut health" outside intestinal failure. No study here compared GLP-2 analogs against each other for tolerability. Long-term exposure evidence is limited, with the three-year pediatric rehabilitation report representing one of the longer observation windows described (PMID 40875041). Reviews of enterohormone therapy have continued to frame the field as evolving rather than settled (PMID 35034035).

As a regulatory matter, teduglutide is the GLP-2 analog approved for short bowel syndrome; native GLP-2 peptide material distributed for laboratory purposes is labelled research-use-only and is not an approved medicine, and research-use-only material is not evaluated for human safety, purity or sterility by any approving authority.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or investigational therapy. It summarises what researchers designed, measured and reported in the cited publications, and it does not describe how any compound should be used.

References

• Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study (Clinical Nutrition, 2024)
• Outcomes of glepaglutide on intestinal absorption and parenteral support in patients with short bowel syndrome (Clinical Nutrition ESPEN, 2025)
• Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment (Clinical Pharmacokinetics, 2023)
• Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure (JPEN: Journal of Parenteral and Enteral Nutrition, 2017)
• A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure (Journal of Pediatric Surgery, 2017)
• Three-year experience with GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome (Pediatric Surgery International, 2025)
• Enterohormone therapy for short bowel syndrome (Current Opinion in Endocrinology, Diabetes, and Obesity, 2022)
• Weaning from Parenteral Nutrition (Gastroenterology Clinics of North America, 2019)
• Progress in intestinal adaptation after enterectomy (Chinese Journal of Gastrointestinal Surgery, 2022)
• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice (Nature Metabolism, 2025)
• Perspective: Prospects for Nutraceutical Support of Intestinal Barrier Function (Advances in Nutrition, 2021)